Wird geladen...
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed sim...
Gespeichert in:
| Veröffentlicht in: | Medicina (Kaunas) |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
MDPI
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6843290/ https://ncbi.nlm.nih.gov/pubmed/31640191 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/medicina55100707 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|